drugset / Trial / NCT02656615
Abiraterone-Rechallenge Study for CRPC Patients
Phase 2
Terminated
4 enrolled
Aurelius Omlin
Cantonal Hospital of St. Gallen · collabUniversity Hospital, Basel, Switzerland · collab
NaSingle-groupOpen-labelTreatment
Summary
To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.
Timeline
- Start
- 2016-01
- Primary completion
- 2017-02
- Completion
- 2017-02
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of Patient accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |